Results obtained with programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have demonstrated remarkable and durable clinical activity in patients with advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.